£5.7m float for weight-fighting OptiBiotix after Ducat deal

A LIFE sciences firm trying to stop people overeating is set to beef up Aim.

After a reverse takeover by Ducat Ventures, OptiBiotix hopes to push on with health innovations[GETTY]

OptiBiotix Health will join the market following a reverse takeover by Aim-listed investor group Ducat Ventures.

It will raise £3.3million with an expected market value of £5.7million and is being advised by Cairn Financial Advisers.

We are at the front line of research to tackle weight related health problems

Stephen O’Hara, OptiBiotix executive chairman

OptiBiotix develops compounds to modify the human microbiome, the collective genome of the microbes in the body, to prevent and manage human disease. It will tackle areas such as obesity, high cholesterol, diabetes and appetite suppression.

The company will use the funds it raises to develop its intellectual property and commercialise its products.

OptiBiotix executive chairman Stephen O’Hara said: “We are at the front line of research into using microbiome science to tackle weight related health problems."